BOUNCE

[oldberkeley]

Because the FDA split the safety question into two parts, which obviously confused the panelists themselves.

The first safety question --has safety been adequately assessed & characterized--no vote. Stock plummets.

The second safety question--is the safety profile adequate for approval--yes vote. Stock soars.

In other words, the company has not shown it to be safe, but if you want to buy it and use it then it should be up to you!

If this doesn't show the ridiculousness of some of these panels, I don't know what does.